FibroGen, Inc (NASDAQ:FGEN) is being projected to post an EPS of $-0.5 for the quarter ended 2016-09-30. 7 days ago the estimate stood at $-0.5 and 30 days ago at $-0.5. Similarly, the projected figure 60 days ago was $-0.5 and 90 days ago it was $-0.5.
The estimates have seen a change of 0% from 7 days ago. During this period, the figure was upwards 0 times and downwards 0 times. During the last 180 days upwards revision in the EPS estimate happened 0 times and downwards revision happened 1 times.
The number of revisions upwards was 0 in 30 days, 2 in 60 days, 2 in 90 days and 1 in 120 days.
The number of revisions downwards was 0 in the last 30 days, 1 in the last 60 days, 1 in the last 90 days and 1 in the last 120 days.
For the quarter ended 1, FibroGen, Inc (NASDAQ:FGEN) had a mean EPS estimate of $-0.5 out of 3 estimates. When the actual figure was announced on 2016-05-09 it was $-0.45, giving a surprise margin of $0.24 or 34.78% per share. The actual EPS yielded a standard deviation of 0.13 from all estimates.
Quarterly Sales Estimates
4 analysts gave FibroGen, Inc (NASDAQ:FGEN) an annual sales estimate of $19.287, if the arithmetic mean of the estimates is considered. The estimate stands at $19.325 if the median is considered. The estimates are for the year 2016. The estimates range from a low of $14 to a high of $24.5, with the standard deviation of the estimates being 4.582%.
In the last week, 4 analysts increased their sales estimate while 4 decreased it. The change in the mean estimate for the period is 0%.
In the last month, 4 analysts increased their sales estimate while 4 decreased it. The change in the mean estimate for the period is 0%.
In last 3 months, 4 analysts increased their sales estimate while 4 decreased it. The change in the mean estimate for the period is -38.783%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...